Pramlintide is a synthetic analogue of human amylin; in a 52-week trial in 651 people with type 1 diabetes, mealtime pramlintide added to insulin lowered HbA1c by 0.29-0.34% more than placebo, with a small weight loss and transient nausea.
established — replicated in humans, or settled by a regulator
every claim resolves to its source
All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
established
Claim: Pramlintide with insulin improved glycaemic and weight control in type 2 diabetes (52-week RCT)standing
resolved
Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.
Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, Weyer C, Kolterman OG
Claim: Pramlintide with insulin improved glycaemic and weight control in type 1 diabetes (52-week RCT)standing
resolved
Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.
Ratner RE, Dickey R, Fineman M, Maggs DG, Shen L, Strobel SA, Weyer C, Kolterman OG
A claim's standing is its latest row in an append-only history; a tombstone names the later evidence and the reason. The Graveyard and the Resurrection Yard.
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.